步长制药Q3净利倍增营收降9% 发财报当天股价跌5.6%

Core Points - The company reported a slight decline in revenue for the first three quarters of 2025, with total revenue at 8.46 billion yuan, a decrease of 0.54% year-on-year [1][4] - Net profit attributable to shareholders saw a significant increase of 177.54%, reaching 868 million yuan, while the net profit excluding non-recurring gains and losses increased by 138.26% to 855 million yuan [1] - The net cash flow from operating activities also improved, rising by 16.20% to 815 million yuan [1] Revenue and Profit Analysis - For Q3 2025, the company reported revenue of 2.80 billion yuan, down 9.02% year-on-year [1] - The net profit for Q3 was 241 million yuan, showing a remarkable growth of 195.44%, while the net profit excluding non-recurring items increased by 71.31% to 236 million yuan [1] Expense Overview - Sales expenses for the first three quarters of 2025 amounted to 3.34 billion yuan, compared to 3.27 billion yuan in the same period last year [2] - Research and development expenses decreased to 154 million yuan from 180 million yuan year-on-year [2] - Total operating costs for the first three quarters were 7.53 billion yuan, down from 7.98 billion yuan in the previous year [4] Market Reaction - Following the financial report release on October 30, the company's stock price fell by 5.64% [4]